Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes

Journal of Pediatrics

Volumn 149, Issue 6, 2006, Pages

  Zdravkovic, Vera ^a   Hamilton, Jill K ^a   Daneman, Denis ^a   Cummings, Elizabeth A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; ISOPHANE INSULIN; LIPID; PIOGLITAZONE; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ARTICLE; CHEMICAL PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33751415019     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.08.049     Document Type: Article

References (23)

1. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 125 (1994) 177-188
2. Holl R.W., Swift P.G., Mortensen H.B., Lynggaard H., Hougaard P., Aanstoot H.J., et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 162 (2003) 22-29
3. Bloch C.A., Clemons P., and Sperling M.A. Puberty decreases insulin sensitivity. J Pediatr 110 (1987) 481-487
4. Amiel S.A., Sherwin R.S., Simonson D.C., Lauritano A.A., and Tamborlane W.V. Impaired insulin action in puberty. A contributing factor to poor control in adolescents with diabetes. N Engl J Med 315 (1986) 215-219
5. Moran A., Jacobs D.R., Steinberger J., Hong C.P., Prineas R., Luepker R., et al. Insulin resistance during puberty. Results from clamp studies in 357 children. Diabetes 48 (1999) 2039-2044
6. Libman I.M., Pietropaolo M., Arslanian S.A., LaPorte R.E., and Becker D.J. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26 (2003) 2871-2875
7. Jefferies C.A., Hamilton J., and Daneman D. Potential adjunctive therapies in adolescents with type 1 diabetes mellitus. Treat Endocrinol 3 (2004) 337-343
8. Sarnblad S., Kroon M., and Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 149 (2003) 323-329
9. Hamilton J., Cummings E., Zdravkovic V., Finegood D., and Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26 (2003) 138-143
10. Chilcott J., Tappenden P., Jones M.L., and Wight J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23 (2001) 1792-1823 discussion 1
11. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L., and The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 22 (2000) 1395-1409
12. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
13. Strowig S.M., and Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 28 (2005) 1562-1567
14. Amiel S.A., Caprio S., Sherwin R.S., Plewe G., Haymond M.W., and Tamborlane W.V. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 72 (1991) 277-282
15. Mortensen H.B., Hougaard P., and The Hvidore Study Group on Childhood Diabetes. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. [published erratum appears in Diabetes Care 1997;20:1216]. Diabetes Care 20 (1997) 714-720
16. Miyazaki Y., Matsuda M., and DeFronzo R.A. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 517-523
17. Rosenstock J., Einhorn D., Hershon K., Glazer N.B., Yu S., and Pioglitazone 014 Study G. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 56 (2002) 251-257
18. Kuczmarski R.J., Ogden C.L., Grummer-Strawn L.M., Flegal K.M., Guo S.S., Wei R., et al. CDC growth charts: United States. Adv Data (2000) 1-27
19. Lawson M.L., Frank M.R., Fry M.K., Perlman K., Sochett E.B., and Daneman D. Intensive diabetes management in adolescents with type 1 diabetes: the importance of intensive follow-up. J Pediatr Endocrinol 13 (2000) 79-84
20. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 (1993) 977-986
21. Chiquette E., Ramirez G., and Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164 (2004) 2097-2104
22. Gillies P.S., and Dunn C.J. Pioglitazone. Drugs 60 (2000) 333-343
23. Hamilton J., and Daneman D. Deteriorating diabetes control during adolescence: physiological or psychosocial?. J Pediatr Endocrinol Metab 15 (2002) 115-126